Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.
Abstract Number : 5539
Abstract Type : Poster Session
Indication : Metastatic Castration Resistant Prostate Cancer
Intervention : Olaparib
Company : AstraZeneca and Merck Sharp & Dohme Corp
Technology : Small Molecule
Baseline FACT-P total score was similar for both treatment arms. FACT-P total and subscale scores during treatment were all higher for olaparib vs pcNHA, with clinically meaningful differences between treatment arms in the adjusted least square (LS) mean changes from baseline in all but FWB and FAPSI-6 (Table). The time to deterioration in FACT-P total and TOI, FAPSI-6, PWB and PCS scores favored olaparib but were not statistically significant, with hazard ratios ranging from 0.68 to 0.94. Further HRQoL results for cohort A will also be presented.
Olaparib delayed deterioration in HRQoL scores vs pcNHA and was associated with better HRQoL functioning over time compared with pcNHA in men with mCRPC and HRR gene alterations.
In men with mCRPC and HRR gene alterations, HRQoL is better preserved during treatment with olaparib compared with the sequential treatment of physician’s choice of new hormonal agent (enzalutamide or abiraterone), further supporting the clinical benefit of improved radiographic progression-free survival
Refer to Metastatic Castration Resistant Prostate Cancer Market report for detailed Insights.